Introducing Ultragenyx Pharmaceutical Inc, a visionary biopharmaceutical company dedicated to revolutionizing the field of rare and ultrarare disease treatments. Today, we proudly unveil our highly anticipated second annual ESG report, showcasing our cutting-edge approach to drug development and unwavering commitment to corporate responsibility.
 
Within this comprehensive report, we illuminate our trailblazing initiatives and transparently disclose our corporate responsibility endeavors. We are steadfast in our pursuit of equitable access to life-changing medicines, generating a profound positive impact on the communities we collaborate with. Moreover, we foster an inclusive and diverse workplace culture while upholding the highest standards of corporate governance.
 
Ultragenyx's ESG strategy is ingeniously structured around six foundational pillars, meticulously aligned with our mission to transform the lives of individuals afflicted by rare diseases. These pillars, aptly named Innovation, Patients, People, Communities, Planet, and Governance, guide our every action, amplifying our potential to make a meaningful difference in the world.
 
“Our company has always had a focus on creating value while also doing good for our communities," said Emil Kakkis, MD, PhD, chief executive officer and president of Ultragenyx.
 
"Our 2022 ESG Report showcases our continued commitment to being a responsible drug developer and making a meaningful difference in peoples’ lives."
 
Ultragenyx ESG Report, a comprehensive testament to our unwavering commitment to sustainability and responsible business practices. Aligned with industry-leading standards, such as the Global Reporting Initiative (GRI) and the Sustainability Accounting Standards Board (SASB), this report showcases our dedication to transparency and accountability.
 
Within its pages, we proudly highlight the United Nations Sustainable Development Goals that resonate most deeply with Ultragenyx's visionary mission. It is a testament to our resolute pursuit of a better future for all.
 
You can delve into the full report and immerse yourself in the extraordinary ESG efforts of Ultragenyx by clicking here.
 
Let us now unveil some of the remarkable highlights from Ultragenyx's 2022 ESG report:
 
Innovation:
Ultragenyx is steadfast in our commitment to delivering groundbreaking, disease-modifying treatments to the rare disease communities who face limited or no treatment options. Here are just a few milestones:
 
Three remarkable gene therapies have advanced into pivotal studies, raising hope for transformative outcomes.

Across 24 countries, we have established over 200 clinical trial sites, ensuring widespread access to our innovative therapies.

Patients:
At Ultragenyx, our dedication to the rare disease community knows no bounds. We strive to provide unwavering support through a range of initiatives, including:
 
Over 3,200 patients have received life-changing Ultragenyx treatments through commercial access and expanded use, bringing renewed hope and improved quality of life.

In honor of Rare Disease Day 2022, we launched a powerful campaign to foster education and access to newborn screening. Additionally, we proudly made matched donations to two esteemed nonprofit organizations, Baby's First Test and Rare Disease Innovation Institute, who tirelessly work in this crucial area.
 
Our unwavering commitment to fostering a diverse, inclusive, safe, and healthy environment sets us apart. We believe in fair and transparent compensation practices, free from bias, ensuring that everyone feels valued and empowered.
 
Just take a look at some remarkable achievements within our People pillar:
 
As of December 2022, approximately 45% of our U.S. employees and a staggering 79% of new hires proudly self-identify as members of diverse populations, fostering an enriching and vibrant workforce.

We believe in continuous growth and development. That's why we offered an impressive array of 70 development workshops, attended by 95% of our dedicated employees.

At Ultragenyx, we're passionate about making a positive impact on the communities we serve. Here's a glimpse into our commitment:
 
Through charitable donations and health-related grants totaling $4.27 million, we proudly supported over 70 patient advocacy organizations in 21 countries. These contributions have reached an astonishing 60,000 healthcare professionals, enhancing medical education and empowering communities.

We're not just a company; we're a force for good. Our Latin America region stood out with 78% employee participation in the first International Day of Service, showcasing our commitment to giving back.

Environmental responsibility is paramount to us. Ultragenyx is dedicated to minimizing our environmental footprint across our operations. Here's what we've accomplished:
 
By purchasing 1,988 megawatt-hours (MWh) of renewable electricity, we effectively avoided an estimated 465 metric tons of carbon dioxide equivalent (CO2e), contributing to a greener and more sustainable future.

Our efforts in waste reduction have been truly remarkable. We diverted 950 pounds of pipette tip boxes from landfills, with 75% of them being recycled into new lab products, embodying our commitment to circularity.

Governance is the bedrock of Ultragenyx's purpose and success. We hold ourselves to the highest standards, ensuring ethical practices, data protection, compliance, and responsible procurement. Some notable achievements include:
 
All our employees underwent comprehensive training on data protection, cyber security, and social media, ensuring that we maintain the utmost integrity in our operations.

We have proudly joined the esteemed International Pharmaceutical Supply Chain Consortium (Rx-360) and actively participate in the Rx-360 Joint Audit Program, solidifying our commitment to industry-leading governance practices.

In recognition of our unwavering dedication, Ultragenyx has received numerous awards and accolades in 2022. We were named the #3 Best Place to Work in the Bay Area for companies with 500-999 employees and ranked #2 for workplace wellness by the San Francisco Business Times. The Boston Globe recognized us as one of the Top Places to Work in Massachusetts. Additionally, we were honored as the Best Leading Rare Disease Medicines & Therapies Company in the 2022 Healthcare and Pharmaceutical Awards by Global Health & Pharma. Furthermore, Ultragenyx proudly secured a place among the Deloitte Technology Fast 500, highlighting our remarkable growth in the technology sector.
 
Join us on our transformative journey, where people thrive, communities flourish, and the planet is protected. Together, we're redefining the future of rare disease medicine.

Introducing Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a leading biopharmaceutical powerhouse dedicated to revolutionizing healthcare for those affected by rare and ultrarare diseases. Today, we proudly unveil our highly anticipated second annual ESG report, showcasing our unwavering commitment to pioneering breakthrough treatments and upholding ethical business practices.
 
In this groundbreaking report, we shine a spotlight on our unparalleled approach to drug development, epitomizing our dedication to innovation and pushing the boundaries of medical science. Our relentless pursuit of transformative solutions is matched by our unwavering transparency regarding our corporate responsibility initiatives. We believe that by sharing our progress, we inspire others to join us in our noble mission.
 
At Ultragenyx, we firmly believe in leaving no one behind. Our steadfast commitment to equitable access to medicines serves as the cornerstone of our purpose. Through our unwavering efforts, we are making a resounding impact on the communities we collaborate with, uplifting lives and fostering hope where it's needed most.
 
We are a trailblazer in cultivating a diverse and inclusive workplace culture. By embracing the unique perspectives and talents of our exceptional team, we create an environment that fuels innovation and empowers individuals to unleash their full potential. At Ultragenyx, everyone's voice matters, and together we drive forward towards a brighter future.
 
As stewards of the planet, we understand our responsibility to protect and preserve our environment. Our comprehensive initiatives reflect our commitment to sustainability and reducing our ecological footprint. By taking proactive steps, we ensure that our pursuit of groundbreaking medicine goes hand in hand with safeguarding the planet we call home.
 
Ultragenyx's unwavering commitment to excellence extends to every facet of our operations. Through our robust corporate governance practices, we maintain the highest standards of accountability, integrity, and ethical conduct. Our commitment to transparency ensures that our stakeholders can trust in our unwavering dedication to doing what is right.
 
Our ESG strategy revolves around six pivotal pillars, each embodying our mission to transform the lives of individuals living with rare diseases. From fostering innovation to championing patient-centricity, empowering our remarkable team, uplifting communities, preserving our planet, and ensuring strong governance, Ultragenyx is leading the charge towards a world where rare diseases are conquered, and hope is restored.
 
“Our company has always had a focus on creating value while also doing good for our communities," said Emil Kakkis, MD, PhD, chief executive officer and president of Ultragenyx. "Our 2022 ESG Report showcases our continued commitment to being a responsible drug developer and making a meaningful difference in peoples’ lives."
 
Experience the power of impact and responsibility in the 2022 Ultragenyx ESG Report, a testament to our unwavering dedication to sustainable growth. This comprehensive report proudly showcases our alignment with the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) indices, as well as our commitment to the UN Sustainable Development Goals that resonate deeply with our vision and mission. Dive into the full report and discover more about Ultragenyx's groundbreaking ESG efforts at https://www.ultragenyx.com/ultra-committed/corporate-responsibility/.
 
Highlights from our remarkable 2022 ESG journey include extraordinary advancements across multiple fronts:
 
Innovation:
Ultragenyx's passion for groundbreaking therapies drives us to deliver novel treatments that have the potential to modify diseases, offering hope to rare disease communities with limited or no treatment options. Brace yourself for our remarkable achievements:
 
Embarked on pivotal studies for three cutting-edge gene therapies.
Established over 200 clinical trial sites across 24 countries by December 2022, solidifying our global impact.

Patients:
At Ultragenyx, our unwavering commitment lies in supporting the rare disease community. We tirelessly strive to develop novel therapies, share our scientific expertise, achieve widespread access to screening and treatment, and actively collaborate with policymakers to drive meaningful change. Witness the tangible impact we've made:
 
Over 3,200 patients have received life-changing Ultragenyx treatments through commercial access and expanded use by December 2022.

In celebration of Rare Disease Day 2022, we launched an impactful campaign promoting education and access to newborn screening. Moreover, we generously matched donations to two exceptional nonprofit organizations, Baby's First Test and Rare Disease Innovation Institute, further amplifying our dedication.

People:
Ultragenyx cherishes diversity, inclusivity, and the well-being of our extraordinary workforce. We provide a safe, healthy environment where everyone can thrive. We're proud to share these milestones:
 
Approximately 45% of our U.S. employees and an impressive 79% of new hires self-identify as members of diverse populations as of December 2022.

Nurturing growth and development, we facilitated 70 development workshops, ensuring that 95% of our employees had the opportunity to enhance their skills and knowledge.

Communities:
Ultragenyx's commitment extends far beyond our organization. We actively support initiatives that create profound impacts in the rare disease community, public health, access to care, STEAM education, and local at-risk communities. Behold our remarkable contributions:
 
Approved charitable donations and health-related grants totaling an astounding $4.27 million, supporting over 70 patient advocacy organizations across 21 countries and providing essential medical education to 60,000 healthcare professionals.

We proudly highlight the tremendous participation of 78% of employees from our Latin America region in the first-ever International Day of Service.

Planet:
Preserving our planet's precious resources is an integral part of Ultragenyx's environmental strategy. We constantly strive to minimize our environmental footprint in every aspect of our business. Witness our commitment in action:
 
Prepare to be amazed as we unveil the remarkable achievements:
 
#3 Best Place to Work in the Bay Area:
Among companies with 500-999 employees, Ultragenyx claimed an impressive spot on the podium. Recognized by the esteemed San Francisco Business Times, our dedication to creating an exceptional workplace culture was celebrated.
 
Workplace Wellness Excellence:
The San Francisco Business Times awarded Ultragenyx the coveted #2 position for workplace wellness. Our unwavering commitment to fostering a healthy and thriving workforce was acknowledged, proving that we prioritize the well-being of our exceptional team.
 
Top Places to Work in Massachusetts:
The Boston Globe bestowed this prestigious recognition upon Ultragenyx, underscoring our exceptional workplace environment. Our commitment to nurturing a supportive and inclusive culture has positioned us among the best in the region.
 
Best Leading Rare Disease Medicines & Therapies Company:
Global Health & Pharma's 2022 Healthcare and Pharmaceutical Awards crowned Ultragenyx as the unrivaled champion in this esteemed category. Our relentless pursuit of innovative treatments and unwavering dedication to rare disease communities set us apart, solidifying our position as a trailblazer in the industry.
 
Deloitte Technology Fast 500:
As one of the fastest-growing companies in the technology sector, Ultragenyx made its mark in the esteemed Deloitte Technology Fast 500. This prestigious recognition showcases our remarkable growth trajectory and reinforces our position at the forefront of cutting-edge medical advancements.
 
Join us on this incredible journey of innovation, impact, and recognition. At Ultragenyx, we continue to push boundaries, setting new standards for excellence and redefining what's possible in the world of rare disease medicine.